Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 125

1.

Combined PARP and Immune Checkpoint Inhibition in Ovarian Cancer.

Lee EK, Konstantinopoulos PA.

Trends Cancer. 2019 Sep;5(9):524-528. doi: 10.1016/j.trecan.2019.06.004. Epub 2019 Jul 15.

PMID:
31474356
2.

Results of an abbreviated Phase Ib study of the HDAC6 inhibitor ricolinostat and paclitaxel in recurrent ovarian, fallopian tube, or primary peritoneal cancer.

Lee EK, Tan-Wasielewski Z, Matulonis UA, Birrer MJ, Wright AA, Horowitz N, Konstantinopoulos PA, Curtis J, Liu JF.

Gynecol Oncol Rep. 2019 Aug 10;29:118-122. doi: 10.1016/j.gore.2019.07.010. eCollection 2019 Aug.

3.

Phase II Study of Avelumab in Patients With Mismatch Repair Deficient and Mismatch Repair Proficient Recurrent/Persistent Endometrial Cancer.

Konstantinopoulos PA, Luo W, Liu JF, Gulhan DC, Krasner C, Ishizuka JJ, Gockley AA, Buss M, Growdon WB, Crowe H, Campos S, Lindeman NI, Hill S, Stover E, Schumer S, Wright AA, Curtis J, Quinn R, Whalen C, Gray KP, Penson RT, Cannistra SA, Fleming GF, Matulonis UA.

J Clin Oncol. 2019 Aug 28:JCO1901021. doi: 10.1200/JCO.19.01021. [Epub ahead of print]

PMID:
31461377
4.

The CHK1 Inhibitor Prexasertib Exhibits Monotherapy Activity in High-Grade Serous Ovarian Cancer Models and Sensitizes to PARP Inhibition.

Parmar K, Kochupurakkal BS, Lazaro JB, Wang ZC, Palakurthi S, Kirschmeier PT, Yang C, Sambel LA, Färkkilä A, Reznichenko E, Reavis HD, Dunn CE, Zou L, Do KT, Konstantinopoulos PA, Matulonis UA, Liu JF, D'Andrea AD, Shapiro GI.

Clin Cancer Res. 2019 Aug 13. doi: 10.1158/1078-0432.CCR-19-0448. [Epub ahead of print]

PMID:
31409614
5.

Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian Carcinoma.

Konstantinopoulos PA, Waggoner S, Vidal GA, Mita M, Moroney JW, Holloway R, Van Le L, Sachdev JC, Chapman-Davis E, Colon-Otero G, Penson RT, Matulonis UA, Kim YB, Moore KN, Swisher EM, Färkkilä A, D'Andrea A, Stringer-Reasor E, Wang J, Buerstatte N, Arora S, Graham JR, Bobilev D, Dezube BJ, Munster P.

JAMA Oncol. 2019 Jun 13. doi: 10.1001/jamaoncol.2019.1048. [Epub ahead of print]

6.

Results from a single arm, single stage phase II trial of trametinib and GSK2141795 in persistent or recurrent cervical cancer.

Liu JF, Gray KP, Wright AA, Campos S, Konstantinopoulos PA, Peralta A, MacNeill K, Morrissey S, Whalen C, Dillon D, Matulonis UA.

Gynecol Oncol. 2019 Jul;154(1):95-101. doi: 10.1016/j.ygyno.2019.05.003. Epub 2019 May 20.

PMID:
31118140
7.

Diagnosis and management of a recurrent polymerase-epsilon (POLE)-mutated endometrial cancer.

Veneris JT, Lee EK, Goebel EA, Nucci MR, Lindeman N, Horowitz NS, Lee L, Raut CP, Crotzer D, Matulonis U, Konstantinopoulos PA, Campos S.

Gynecol Oncol. 2019 Jun;153(3):471-478. doi: 10.1016/j.ygyno.2019.03.247. Epub 2019 Mar 29.

PMID:
30935717
8.

Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial.

Konstantinopoulos PA, Barry WT, Birrer M, Westin SN, Cadoo KA, Shapiro GI, Mayer EL, O'Cearbhaill RE, Coleman RL, Kochupurakkal B, Whalen C, Curtis J, Farooq S, Luo W, Eismann J, Buss MK, Aghajanian C, Mills GB, Palakurthi S, Kirschmeier P, Liu J, Cantley LC, Kaufmann SH, Swisher EM, D'Andrea AD, Winer E, Wulf GM, Matulonis UA.

Lancet Oncol. 2019 Apr;20(4):570-580. doi: 10.1016/S1470-2045(18)30905-7. Epub 2019 Mar 14.

PMID:
30880072
9.

POLE-mutated clear cell cervical cancer associated with in-utero diethylstilbestrol exposure.

Lee EK, Lindeman NI, Matulonis UA, Konstantinopoulos PA.

Gynecol Oncol Rep. 2019 Jan 29;28:15-17. doi: 10.1016/j.gore.2019.01.012. eCollection 2019 May.

10.

PARP Inhibition Elicits STING-Dependent Antitumor Immunity in Brca1-Deficient Ovarian Cancer.

Ding L, Kim HJ, Wang Q, Kearns M, Jiang T, Ohlson CE, Li BB, Xie S, Liu JF, Stover EH, Howitt BE, Bronson RT, Lazo S, Roberts TM, Freeman GJ, Konstantinopoulos PA, Matulonis UA, Zhao JJ.

Cell Rep. 2018 Dec 11;25(11):2972-2980.e5. doi: 10.1016/j.celrep.2018.11.054.

11.

DYNLL1 binds to MRE11 to limit DNA end resection in BRCA1-deficient cells.

He YJ, Meghani K, Caron MC, Yang C, Ronato DA, Bian J, Sharma A, Moore J, Niraj J, Detappe A, Doench JG, Legube G, Root DE, D'Andrea AD, Drané P, De S, Konstantinopoulos PA, Masson JY, Chowdhury D.

Nature. 2018 Nov;563(7732):522-526. doi: 10.1038/s41586-018-0670-5. Epub 2018 Oct 31.

PMID:
30464262
12.

Targeting MYC dependency in ovarian cancer through inhibition of CDK7 and CDK12/13.

Zeng M, Kwiatkowski NP, Zhang T, Nabet B, Xu M, Liang Y, Quan C, Wang J, Hao M, Palakurthi S, Zhou S, Zeng Q, Kirschmeier PT, Meghani K, Leggett AL, Qi J, Shapiro GI, Liu JF, Matulonis UA, Lin CY, Konstantinopoulos PA, Gray NS.

Elife. 2018 Nov 13;7. pii: e39030. doi: 10.7554/eLife.39030.

13.

PARP Inhibition Induces Enrichment of DNA Repair-Proficient CD133 and CD117 Positive Ovarian Cancer Stem Cells.

Bellio C, DiGloria C, Foster R, James K, Konstantinopoulos PA, Growdon WB, Rueda BR.

Mol Cancer Res. 2019 Feb;17(2):431-445. doi: 10.1158/1541-7786.MCR-18-0594. Epub 2018 Nov 6.

PMID:
30401718
14.

Targeting DNA Damage Response and Repair as a Therapeutic Strategy for Ovarian Cancer.

Konstantinopoulos PA, Matulonis UA.

Hematol Oncol Clin North Am. 2018 Dec;32(6):997-1010. doi: 10.1016/j.hoc.2018.07.006. Review.

PMID:
30390770
15.

Prediction of DNA Repair Inhibitor Response in Short-Term Patient-Derived Ovarian Cancer Organoids.

Hill SJ, Decker B, Roberts EA, Horowitz NS, Muto MG, Worley MJ Jr, Feltmate CM, Nucci MR, Swisher EM, Nguyen H, Yang C, Morizane R, Kochupurakkal BS, Do KT, Konstantinopoulos PA, Liu JF, Bonventre JV, Matulonis UA, Shapiro GI, Berkowitz RS, Crum CP, D'Andrea AD.

Cancer Discov. 2018 Nov;8(11):1404-1421. doi: 10.1158/2159-8290.CD-18-0474. Epub 2018 Sep 13.

PMID:
30213835
16.

Durable response in a woman with recurrent low-grade endometrioid endometrial cancer and a germline BRCA2 mutation treated with a PARP inhibitor.

Gockley AA, Kolin DL, Awtrey CS, Lindeman NI, Matulonis UA, Konstantinopoulos PA.

Gynecol Oncol. 2018 Aug;150(2):219-226. doi: 10.1016/j.ygyno.2018.05.028. Epub 2018 Jun 22.

PMID:
29937315
17.

PARP Inhibitors in Ovarian Cancer: A Trailblazing and Transformative Journey.

Konstantinopoulos PA, Matulonis UA.

Clin Cancer Res. 2018 Sep 1;24(17):4062-4065. doi: 10.1158/1078-0432.CCR-18-1314. Epub 2018 Jun 5.

18.

Assessment of a Chemotherapy Response Score (CRS) System for Tubo-Ovarian High-Grade Serous Carcinoma (HGSC).

Ditzel HM, Strickland KC, Meserve EE, Stover E, Konstantinopoulos PA, Matulonis UA, Muto MG, Liu JF, Feltmate C, Horowitz N, Berkowitz RS, Gupta M, Hecht JL, Lin DI, Jochumsen KM, Welch WR, Hirsch MS, Quade BJ, Lee KR, Crum CP, Mutter GL, Nucci MR, Howitt BE.

Int J Gynecol Pathol. 2019 May;38(3):230-240. doi: 10.1097/PGP.0000000000000513.

PMID:
29750700
19.

Phase II study of single-agent cabozantinib in patients with recurrent clear cell ovarian, primary peritoneal or fallopian tube cancer (NRG-GY001).

Konstantinopoulos PA, Brady WE, Farley J, Armstrong A, Uyar DS, Gershenson DM.

Gynecol Oncol. 2018 Jul;150(1):9-13. doi: 10.1016/j.ygyno.2018.04.572. Epub 2018 May 5.

20.

Multifaceted Impact of MicroRNA 493-5p on Genome-Stabilizing Pathways Induces Platinum and PARP Inhibitor Resistance in BRCA2-Mutated Carcinomas.

Meghani K, Fuchs W, Detappe A, Drané P, Gogola E, Rottenberg S, Jonkers J, Matulonis U, Swisher EM, Konstantinopoulos PA, Chowdhury D.

Cell Rep. 2018 Apr 3;23(1):100-111. doi: 10.1016/j.celrep.2018.03.038.

21.

From checkpoint to checkpoint: DNA damage ATR/Chk1 checkpoint signalling elicits PD-L1 immune checkpoint activation.

Mouw KW, Konstantinopoulos PA.

Br J Cancer. 2018 Apr;118(7):933-935. doi: 10.1038/s41416-018-0017-x. Epub 2018 Mar 13.

22.

Targeted Next-Generation Sequencing Reveals Clinically Actionable BRAF and ESR1 Mutations in Low-Grade Serous Ovarian Carcinoma.

Stover EH, Feltmate C, Berkowitz RS, Lindeman NI, Matulonis UA, Konstantinopoulos PA.

JCO Precis Oncol. 2018;2018. doi: 10.1200/PO.18.00135. Epub 2018 Nov 8. No abstract available.

23.

EZH2 promotes degradation of stalled replication forks by recruiting MUS81 through histone H3 trimethylation.

Rondinelli B, Gogola E, Yücel H, Duarte AA, van de Ven M, van der Sluijs R, Konstantinopoulos PA, Jonkers J, Ceccaldi R, Rottenberg S, D'Andrea AD.

Nat Cell Biol. 2017 Nov;19(11):1371-1378. doi: 10.1038/ncb3626. Epub 2017 Oct 16.

PMID:
29035360
24.

DNA Damage and Repair Biomarkers of Immunotherapy Response.

Mouw KW, Goldberg MS, Konstantinopoulos PA, D'Andrea AD.

Cancer Discov. 2017 Jul;7(7):675-693. doi: 10.1158/2159-8290.CD-17-0226. Epub 2017 Jun 19. Review.

25.

Clear cell ovarian cancers with microsatellite instability: A unique subset of ovarian cancers with increased tumor-infiltrating lymphocytes and PD-1/PD-L1 expression.

Howitt BE, Strickland KC, Sholl LM, Rodig S, Ritterhouse LL, Chowdhury D, D'Andrea AD, Matulonis UA, Konstantinopoulos PA.

Oncoimmunology. 2017 Jan 6;6(2):e1277308. doi: 10.1080/2162402X.2016.1277308. eCollection 2017.

26.

Evolutionarily conserved serum microRNAs predict radiation-induced fatality in nonhuman primates.

Fendler W, Malachowska B, Meghani K, Konstantinopoulos PA, Guha C, Singh VK, Chowdhury D.

Sci Transl Med. 2017 Mar 1;9(379). pii: eaal2408. doi: 10.1126/scitranslmed.aal2408.

27.

Predicted neoantigen load in non-hypermutated endometrial cancers: Correlation with outcome and tumor-specific genomic alterations.

Shukla SA, Howitt BE, Wu CJ, Konstantinopoulos PA.

Gynecol Oncol Rep. 2016 Dec 29;19:42-45. doi: 10.1016/j.gore.2016.12.009. eCollection 2017 Feb.

28.

Erratum: Replication fork stability confers chemoresistance in BRCA-deficient cells.

Chaudhuri AR, Callen E, Ding X, Gogola E, Duarte AA, Lee JE, Wong N, Lafarga V, Calvo JA, Panzarino NJ, John S, Day A, Crespo AV, Shen B, Starnes LM, de Ruiter JR, Daniel JA, Konstantinopoulos PA, Cortez D, Cantor SB, Fernandez-Capetillo O, Ge K, Jonkers J, Rottenberg S, Sharan SK, Nussenzweig A.

Nature. 2016 Nov 17;539(7629):456. doi: 10.1038/nature19826. Epub 2016 Sep 28. No abstract available.

PMID:
27680696
29.

Biomarkers of Response and Resistance to DNA Repair Targeted Therapies.

Stover EH, Konstantinopoulos PA, Matulonis UA, Swisher EM.

Clin Cancer Res. 2016 Dec 1;22(23):5651-5660. Epub 2016 Sep 27. Review.

30.

Replication fork stability confers chemoresistance in BRCA-deficient cells.

Ray Chaudhuri A, Callen E, Ding X, Gogola E, Duarte AA, Lee JE, Wong N, Lafarga V, Calvo JA, Panzarino NJ, John S, Day A, Crespo AV, Shen B, Starnes LM, de Ruiter JR, Daniel JA, Konstantinopoulos PA, Cortez D, Cantor SB, Fernandez-Capetillo O, Ge K, Jonkers J, Rottenberg S, Sharan SK, Nussenzweig A.

Nature. 2016 Jul 21;535(7612):382-7. doi: 10.1038/nature18325. Erratum in: Nature. 2016 Nov 17;539(7629):456.

31.

Epstein-Barr Virus Infection of Mammary Epithelial Cells Promotes Malignant Transformation.

Hu H, Luo ML, Desmedt C, Nabavi S, Yadegarynia S, Hong A, Konstantinopoulos PA, Gabrielson E, Hines-Boykin R, Pihan G, Yuan X, Sotiriou C, Dittmer DP, Fingeroth JD, Wulf GM.

EBioMedicine. 2016 Jul;9:148-160. doi: 10.1016/j.ebiom.2016.05.025. Epub 2016 May 21.

32.

Prognostic implications of reproductive and lifestyle factors in ovarian cancer.

Poole EM, Konstantinopoulos PA, Terry KL.

Gynecol Oncol. 2016 Sep;142(3):574-87. doi: 10.1016/j.ygyno.2016.05.014. Epub 2016 May 29. Review.

PMID:
27189457
33.

Morphologic correlates of molecular alterations in extrauterine Müllerian carcinomas.

Ritterhouse LL, Nowak JA, Strickland KC, Garcia EP, Jia Y, Lindeman NI, Macconaill LE, Konstantinopoulos PA, Matulonis UA, Liu J, Berkowitz RS, Nucci MR, Crum CP, Sholl LM, Howitt BE.

Mod Pathol. 2016 Aug;29(8):893-903. doi: 10.1038/modpathol.2016.82. Epub 2016 May 6.

34.

Nucleotide excision repair (NER) alterations as evolving biomarkers and therapeutic targets in epithelial cancers.

Mouw KW, D'Andrea AD, Konstantinopoulos PA.

Oncoscience. 2015 Dec 29;2(12):942-3. eCollection 2015. No abstract available.

35.

Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer.

Strickland KC, Howitt BE, Shukla SA, Rodig S, Ritterhouse LL, Liu JF, Garber JE, Chowdhury D, Wu CJ, D'Andrea AD, Matulonis UA, Konstantinopoulos PA.

Oncotarget. 2016 Mar 22;7(12):13587-98. doi: 10.18632/oncotarget.7277.

36.

Platinum and PARP Inhibitor Resistance Due to Overexpression of MicroRNA-622 in BRCA1-Mutant Ovarian Cancer.

Choi YE, Meghani K, Brault ME, Leclerc L, He YJ, Day TA, Elias KM, Drapkin R, Weinstock DM, Dao F, Shih KK, Matulonis U, Levine DA, Konstantinopoulos PA, Chowdhury D.

Cell Rep. 2016 Jan 26;14(3):429-439. doi: 10.1016/j.celrep.2015.12.046. Epub 2016 Jan 7.

37.

Neoepitopes and CD3-Positive and CD8-Positive Cells in Polymerase e-Mutated and Microsatellite-Instable Endometrial Cancers--Reply.

Howitt BE, Shukla SA, Konstantinopoulos PA.

JAMA Oncol. 2016 Jan;2(1):141-2. doi: 10.1001/jamaoncol.2015.3903. No abstract available.

PMID:
26767553
38.

Genomic testing and precision medicine--What does this mean for gynecologic oncology?

Liu J, Konstantinopoulos PA, Matulonis UA.

Gynecol Oncol. 2016 Jan;140(1):3-5. doi: 10.1016/j.ygyno.2015.12.001. Epub 2015 Dec 4. No abstract available.

PMID:
26657840
39.

Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer.

Konstantinopoulos PA, Ceccaldi R, Shapiro GI, D'Andrea AD.

Cancer Discov. 2015 Nov;5(11):1137-54. doi: 10.1158/2159-8290.CD-15-0714. Epub 2015 Oct 13. Review.

40.

Association of Polymerase e-Mutated and Microsatellite-Instable Endometrial Cancers With Neoantigen Load, Number of Tumor-Infiltrating Lymphocytes, and Expression of PD-1 and PD-L1.

Howitt BE, Shukla SA, Sholl LM, Ritterhouse LL, Watkins JC, Rodig S, Stover E, Strickland KC, D'Andrea AD, Wu CJ, Matulonis UA, Konstantinopoulos PA.

JAMA Oncol. 2015 Dec;1(9):1319-23. doi: 10.1001/jamaoncol.2015.2151.

PMID:
26181000
41.

Resistance to therapy in BRCA2 mutant cells due to loss of the nucleosome remodeling factor CHD4.

Guillemette S, Serra RW, Peng M, Hayes JA, Konstantinopoulos PA, Green MR, Cantor SB.

Genes Dev. 2015 Mar 1;29(5):489-94. doi: 10.1101/gad.256214.114.

42.

Homologous-recombination-deficient tumours are dependent on Polθ-mediated repair.

Ceccaldi R, Liu JC, Amunugama R, Hajdu I, Primack B, Petalcorin MI, O'Connor KW, Konstantinopoulos PA, Elledge SJ, Boulton SJ, Yusufzai T, D'Andrea AD.

Nature. 2015 Feb 12;518(7538):258-62. doi: 10.1038/nature14184. Epub 2015 Feb 2.

43.

A unique subset of epithelial ovarian cancers with platinum sensitivity and PARP inhibitor resistance.

Ceccaldi R, O'Connor KW, Mouw KW, Li AY, Matulonis UA, D'Andrea AD, Konstantinopoulos PA.

Cancer Res. 2015 Feb 15;75(4):628-34. doi: 10.1158/0008-5472.CAN-14-2593. Epub 2015 Jan 29.

44.

POLE mutations as an alternative pathway for microsatellite instability in endometrial cancer: implications for Lynch syndrome testing.

Konstantinopoulos PA, Matulonis UA.

Cancer. 2015 Feb 1;121(3):331-4. doi: 10.1002/cncr.29057. Epub 2014 Sep 15. No abstract available.

45.

Complications of pelvic radiation in patients treated for gynecologic malignancies.

Viswanathan AN, Lee LJ, Eswara JR, Horowitz NS, Konstantinopoulos PA, Mirabeau-Beale KL, Rose BS, von Keudell AG, Wo JY.

Cancer. 2014 Dec 15;120(24):3870-83. doi: 10.1002/cncr.28849. Epub 2014 Jul 23. Review.

46.

An ex vivo assay of XRT-induced Rad51 foci formation predicts response to PARP-inhibition in ovarian cancer.

Shah MM, Dobbin ZC, Nowsheen S, Wielgos M, Katre AA, Alvarez RD, Konstantinopoulos PA, Yang ES, Landen CN.

Gynecol Oncol. 2014 Aug;134(2):331-7. doi: 10.1016/j.ygyno.2014.05.009. Epub 2014 May 15.

47.

Sublethal concentrations of 17-AAG suppress homologous recombination DNA repair and enhance sensitivity to carboplatin and olaparib in HR proficient ovarian cancer cells.

Choi YE, Battelli C, Watson J, Liu J, Curtis J, Morse AN, Matulonis UA, Chowdhury D, Konstantinopoulos PA.

Oncotarget. 2014 May 15;5(9):2678-87.

48.

Immunohistochemical loss of BRCA1 protein in uterine serous carcinoma.

Hecht JL, Konstantinopoulos PA, Awtrey CS, Soslow RA.

Int J Gynecol Pathol. 2014 May;33(3):282-7. doi: 10.1097/PGP.0b013e318290409c.

PMID:
24681740
49.

Suberoylanilide hydroxamic acid (SAHA) enhances olaparib activity by targeting homologous recombination DNA repair in ovarian cancer.

Konstantinopoulos PA, Wilson AJ, Saskowski J, Wass E, Khabele D.

Gynecol Oncol. 2014 Jun;133(3):599-606. doi: 10.1016/j.ygyno.2014.03.007. Epub 2014 Mar 11.

50.

PARP inhibitors in ovarian cancer: current status and future promise.

Liu JF, Konstantinopoulos PA, Matulonis UA.

Gynecol Oncol. 2014 May;133(2):362-9. doi: 10.1016/j.ygyno.2014.02.039. Epub 2014 Mar 4. Review.

PMID:
24607283

Supplemental Content

Loading ...
Support Center